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Abstract
Background: Pancreatic cancer is the fourth largest cause of cancer death in the United States and Europe with
over 100,000 deaths per year in Europe alone. The overall 5-year survival ranges from 2–7 % and has hardly
improved over the last two decades. Approximately 15 % of all patients have resectable disease at diagnosis,
and of those, only a subgroup has a resectable tumour at surgical exploration. Data from cohort studies have
suggested that outcome can be improved by preoperative radiochemotherapy, but data from well-designed
randomized studies are lacking. Our PREOPANC phase III trial aims to test the hypothesis that median overall
survival of patients with resectable or borderline resectable pancreatic cancer can be improved with
preoperative radiochemotherapy.
Methods/design: The PREOPANC trial is a randomized, controlled, multicentric superiority trial, initiated by
the Dutch Pancreatic Cancer Group. Patients with (borderline) resectable pancreatic cancer are randomized to
A: direct explorative laparotomy or B: after negative diagnostic laparoscopy, preoperative radiochemotherapy,
followed by explorative laparotomy. A hypofractionated radiation scheme of 15 fractions of 2.4 gray (Gy) is
combined with a course of gemcitabine, 1,000 mg/m2/dose on days 1, 8 and 15, preceded and followed by
a modified course of gemcitabine. The target volumes of radiation are delineated on a 4D CT scan, where at
least 95 % of the prescribed dose of 36 Gy in 15 fractions should cover 98 % of the planning target volume.
Standard adjuvant chemotherapy is administered in both treatment arms after resection (six cycles in arm A
and four in arm B). In total, 244 patients will be randomized in 17 hospitals in the Netherlands. The primary
endpoint is overall survival by intention to treat. Secondary endpoints are (R0) resection rate, disease-free
survival, time to locoregional recurrence or distant metastases and perioperative complications. Secondary
endpoints for the experimental arm are toxicity and radiologic and pathologic response.
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Discussion: The PREOPANC trial is designed to investigate whether preoperative radiochemotherapy improves
overall survival by means of increased (R0) resection rates in patients with resectable or borderline resectable
pancreatic cancer.
Trial registration: Trial open for accrual: 3 April 2013
The Netherlands National Trial Register – NTR3709 (8 November 2012)
EU Clinical Trials Register – 2012-003181-40 (11 December 2012)
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Background
Pancreatic cancer is the fourth largest cause of cancer
death in the United States and Europe with over 100,000
deaths per year in Europe alone [1, 2]. The overall 5-year
survival ranges from 2–7 % and has hardly improved over
the last two decades [1, 3, 4]. Surgery is the main treat-
ment option that may lead to cure. After radical resection
the median survival is about 15–20 months and the 5-year
overall survival ranges from 8–25 % [5–8]. The outcome
may be improved by preoperative radiochemotherapy, but
data from well-designed randomized studies are lacking
[9]. Recently, a monocentric randomized controlled trial
on preoperative radiochemotherapy was terminated early
because of poor recruitment [10]. Research should be fo-
cused on a coordinated multidisciplinary approach to im-
prove results for patients with resectable and borderline
resectable pancreatic cancer.
Pancreatoduodenectomy is the commonly accepted
surgical treatment for resectable cancer of the pancre-
atic head. The goal of pancreatoduodenectomy is to
perform a microscopically complete (R0) resection of
the tumour. A microscopically incomplete resection
(R1) worsens the prognosis [11–14]. The resection
rate depends upon the preoperative radiologic workup
with high quality CT scan, MRI and/or laparoscopy,
and is reported as 60 % without and 82 % with lapar-
oscopy [15]. The R0 resection rate varies from 25–
84 % and depends upon the dissection technique and
pathological workup [16].
In the 2014 Dutch National Audit 33 % of patients ap-
peared to have an irresectable tumour at explorative
laparotomy after radiologic assessment [17]. The most
important prognostic factors are tumour size and vascu-
lar involvement; large tumours (>2 cm) have a worse
prognosis than smaller tumours [11, 18]. Tumours
≤2 cm without vessel involvement, classified as T1 ac-
cording to the UICC TNM classification, have the best
chance of an R0 resection and may not benefit from pre-
operative radiochemotherapy. Encasements of the celiac
axis, superior mesenteric artery (SMA) or common hep-
atic artery (CHA) are considered contraindications for
resection. Resectability in the case of involvement of the
portal vein and/or the superior mesenteric vein (PV/
SMV) is under debate.
Surgical series vary in criteria for resectability. Series
of patients undergoing curative surgery tend to focus on
survival data of the patients who actually underwent a
successful resection. Reporting data by intention to treat,
that is, on all patients who were selected for explorative
surgery, whether or not the resection was performed at
all, would provide more relevant data. Data from studies
reporting the survival of patient by intent to treat after
preoperative therapy report a median overall survival
(mOS) of 17 months [19–25]. Studies of explorative sur-
gery without preoperative treatment analysing survival
by intention to treat report mOS between 10 and
12 months [22, 26, 27]. These survival rates are not
comparable with those of studies on postoperative adju-
vant (radio)chemotherapy. In this last category, the me-
dian survival is better due to selection bias, since in
these studies only patients who were fit enough after a
successful resection participated. In the systematic re-
view of Gillen et al., the actual resection rates are in the
order of 70–85 % of patients who were considered to
have a resectable tumour at preoperative workup (with
or without preoperative radiochemotherapy). Reporting
data by intention to treat seems advisable and would
change outcome figures of surgical series significantly
[9]. Therefore, future studies in patients with resectable
pancreatic cancer should have a prospective randomized
design, with analyses by intention to treat, to be able to
investigate not only the improvement of the prognosis
as such, but also the potential improvement of the resec-
tion rate.
The rationale for preoperative therapy in pancreatic
cancer is multifold. First, radiochemotherapy adminis-
tered before surgery to non-dissected, well-oxygenated
tissue may maximize any potential benefit of both radi-
ation and chemotherapy, as compared to postoperative
radiochemotherapy. Second, preoperative radiochemo-
therapy may decrease tumour volume, thus improving
resectability and minimize regional nodal disease, hence
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reducing the risk of loco-regional recurrence. Third, it
may downstage disease by sterilizing the peripheral ex-
tent of tumour infiltration, resulting in an increased pro-
portion of R0 resections. Randomized controlled trials
investigating the effect of postoperative adjuvant radio-
chemotherapy were all negative [28–32]. A number of
prospective, single arm, single centre studies suggested
an improved resectability rate as well as a higher propor-
tion of R0 resections by preoperative radiochemotherapy
[19–23, 33–38]. Although the numbers of patients are
too small for firm conclusions, the results of studies in
patients with borderline resectable tumours who re-
ceived preoperative treatment suggest that this strategy
is not inferior and may even be better compared with
patients who had a resection without preoperative treat-
ment [22]. This was also the conclusion of a meta-
analysis of Gillen et al., which included 111 studies of
preoperative treatment, 56 of which were performed in
patients with tumours that were initially considered irre-
sectable. In these studies, of 147 patients with initially
irresectable tumours, 33 % of patients underwent a suc-
cessful resection after preoperative therapy. Remarkably,
the R0 resection rate (79 %) and the median survival
(20.5 months) in this group were similar to the results of
studies in patients with primarily resectable tumours [9].
Artinyan et al. performed a population-based regional
retrospective review of 354 patients with resected pan-
creatic cancer and observed a better median survival for
preoperative therapy compared to postoperative adju-
vant therapy (34 versus 19 months, respectively, HR
0.57, p = 0.013) [39]; keep in mind that these are differ-
ent groups.
The hypothesis that preoperative radiochemotherapy
may improve the outcome of resectable and borderline
resectable pancreatic cancer is worth testing [40]. In a
recent European consensus, preoperative radiochemo-
therapy was considered as one of the main directions for
future clinical research [41]. Within the Dutch Pancreatic
Cancer Group (DPCG), this concept has been further de-
veloped into the clinical randomized, controlled, multi-
centre randomized phase III PREOPANC trial. This trial
tests the hypothesis that preoperative radiochemotherapy
followed by explorative surgery compared to direct ex-
plorative surgery may improve the survival of patients
with resectable or borderline resectable pancreatic cancer.
This trial will be analysed by intention to treat.
Methods/design
Design
The PREOPANC trial is a randomized, controlled, multi-
centre trial, initiated by the DPCG. Patients with resect-
able or borderline resectable tumours (see Table 1) are
randomized to arm A: direct explorative laparotomy or
arm B: preoperative radiochemotherapy, followed by ex-
plorative laparotomy. In both arms patients receive
standard adjuvant chemotherapy after resection.
The aim of the study is to investigate whether pre-
operative radiochemotherapy will improve the overall
survival by intention to treat for patients with resectable
or borderline resectable pancreatic adenocarcinoma
through improvement of the resection rate and improve-
ment of the R0 resection rate.
Study endpoints
The primary endpoint is overall survival by intention to
treat. Secondary endpoints include the resection rate,
the R0 resection rate, disease-free survival, time to loco-
regional recurrence or distant metastases and postopera-
tive complications. A loco-regional failure is any persist-
ent or new sign of tumour in the original tumour
location or in the N1 lymph node areas. Secondary end-
points for the patients in the preoperative radiochemo-
therapy arm also include the toxicity according to
Common Terminology Criteria for Adverse Events
(CTC-AE) version 4 [42], as well as response to radio-
chemotherapy according to radiologic Response Evalu-
ation Criteria in Solid Tumors (RECIST) criteria version
1.1 [43] and pathologic response rates after preoperative
radiochemotherapy [44].
Statistical aspects
The median overall survival by intention to treat is esti-
mated to be 11 months in patients treated by explorative
laparotomy without preoperative treatment [22, 26, 27].
The study is designed to show a benefit in median overall
survival for radiochemotherapy of 6 months (to 17 months),
which corresponds to a hazard ratio of 0.651, based on pre-
vious studies reporting survival by intention to treat with
preoperative radiochemotherapy [19–25].
To achieve 80 % power for the expected median sur-
vival difference, taking into account the planned interim
analysis and assuming 10 % dropouts, the calculated
sample size of the study is 122 patients in each group,
Table 1 Dutch Pancreatic Cancer Group definitions for resectability of pancreatic adenocarcinoma (DPCG, 2012)
SMA Celiac axis CHA SMV-PV
Resectable (all four required) no contact no contact no contact ≤90° contact
Borderline resectable (minimally one required) ≤90° contact ≤90° contact ≤90° contact ≤90°-270° contact, and no occlusion
Irresectable (minimally one required) contact > 90° contact > 90° contact > 90° contact > 270° or occlusion
SMA superior mesenteric artery, CHA common hepatic artery, SMV superior mesenteric vein, PV portal vein
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adding up to a total of 244 patients, with a total number of
176 events required. The total duration of patient accrual is
expected to exceed the initially intended 36 months by
about 15 months. The sample size is not separately calcu-
lated for both stratification groups (resectable/borderline
resectable), but subset analyses for these strata are planned.
A formal interim analysis of all-cause survival will be
performed by an independent data monitoring commit-
tee at appointed time points to be able to stop the study
in case of an unexpectedly high efficacy difference or fu-
tility. All analyses will be performed primarily by
intention to treat. The stratified log rank test statistics
will be used to compare the Kaplan-Meier survival
curves of the two randomization groups. The compari-
son of the time to loco-regional failure and the time to
distant metastases between the randomization groups
will be analysed by a competing risk model. Subset ana-
lyses of the resectable and borderline resectable tumours
are planned.
Study population
Patients meeting the DPCG definitions for resectable or
borderline resectable pancreatic adenocarcinoma are eli-
gible. In this study, borderline resectable tumours are tu-
mours with arterial abutment less than 90° contact and/or
venous involvement (90–270° contact but without vessel
occlusion; Table 1) on CT/MRI. There is currently consen-
sus throughout the Netherlands about these strict criteria.
The definition for (borderline) resectable pancreatic tu-
mours differs from those of other countries and the Na-
tional Comprehensive Cancer Network (NCCN) definition.
Inclusion criteria
Inclusion criteria are: histologically or cytologically con-
firmed adenocarcinoma of the pancreas; primarily resect-
able or borderline resectable tumours (Table 1), with the
ability to undergo surgery and radiochemotherapy (WHO
≤1 and normal blood count, leucocytes, platelets, haemo-
globin and adequate renal function), with provision of
written informed consent.
Exclusion criteria
Exclusion criteria are: T1 resectable tumours, locally ad-
vanced, irresectable tumours or distant metastases; cyto-
logically proven N2 lymph node metastases; carcinoma
of the papilla of Vater or distal bile duct; previous active
malignancy shorter than 5 years before diagnosis of pan-
creatic cancer or co-morbidity or previous treatment
precluding surgery or radiochemotherapy.
Randomization
After confirmation of eligibility including written in-
formed consent, patients are randomized, and stratified
for resectability (resectable versus borderline resectable)
and for the participating institution. Randomization is
between arm A: (standard) explorative laparotomy with
resection if possible, followed by adjuvant chemotherapy,
and arm B: (experimental) preoperative radiochemother-
apy after diagnostic laparoscopy, to rule out small liver
or peritoneal metastases followed by explorative surgery
with resection if possible followed by the remaining ad-
juvant chemotherapy. The minimum requirements for a
successful laparoscopy are visualization of the periton-
eum, liver surface, diaphragm and base of the large
bowel mesenterium. In both study arms the indications
not to continue with a resection will be based upon the
finding of distant metastases or the loco-regional exten-
sion of the disease, in particular vascular involvement.
In case of irresectability or metastasis, such a resection
is considered impossible or inappropriate, and it is left to
the discretion of the treating surgeon how to proceed with
the operation. For instance, palliative bypass surgery may
be performed. In the experimental arm, after radiochemo-
therapy an exploration is performed unless post radioche-
motherapy imaging reveals distant metastases or clear-cut
loco-regional progression to irresectable disease.
Treatment
Arm A: direct explorative laparotomy
The explorative laparotomy will be performed within
4 weeks after randomization. The indication to continue
with a resection will be based upon the absence of dis-
tant metastases and the loco-regional extension of the
disease, in particular massive vascular involvement. Sus-
pected metastases or invasion of vascular structures, if
suspected, must be proven histologically by frozen sec-
tion. If resection is performed, the standard procedure
depending on the location of the cancer is the pylorus-
preserving pancreatoduodenectomy (PPPD) with re-
moval of lymph nodes at the right side of the portal vein
or a distal pancreatectomy. Both procedures are per-
formed according to a consensus statement by the Inter-
national Study Group on Pancreatic Surgery [45].
After resection, adjuvant gemcitabine is given. Gemcita-
bine is administered at 1000 mg/m2/dose on days 1, 8,
and 15 in six cycles of 28 days (4 weeks) each [25, 38, 46].
Arm B: preoperative radiochemotherapy followed by
explorative laparotomy
Diagnostic laparoscopy is performed after randomization
but prior to the start of radiochemotherapy to rule out
peritoneal or small liver metastases that are not visible
with imaging. The first chemotherapy cycle has to start
not later than 4 weeks after randomization. If needed,
preoperative biliary drainage will be performed, prefera-
bly with self-expandable metal stents.
A hypofractionated scheme radiotherapy of 15 frac-
tions of 2.4 Gy in 3 weeks will be applied, combined
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with a course of full dose gemcitabine, 1000 mg/m2 on
days 1, 8 and 15 followed by one week rest. This course
is preceded and followed by a modified course of gemci-
tabine, 1000 mg/m2 on days 1 and 8 followed by one
week rest, as described previously [25].
The target volumes are delineated on a 4D CT scan
with intravenous contrast enhancement. The target vol-
umes include the gross tumour volume (GTV), which in-
cludes the pancreatic tumour plus pathologic neighbouring
lymph nodes, as described on the diagnostic CT scan. The
clinical target volume (CTV) includes the GTV plus pos-
sible tumour extension of 5 mm. The internal target vol-
ume (ITV) is the sum of the individual defined CTVs in all
phases of respiration on the 4D CT scan. Finally, the plan-
ning target volume (PTV) is composite, including the ITV
plus 10 mm margin. No elective lymph node areas are in-
cluded in the target volumes. This delineation is done with
the diagnostic CT scan (and/or MRI) available in close co-
operation between the radiation oncologist and diagnostic
radiologist. Scans should be matched when possible with
pre-treatment diagnostic CT or MR images if these provide
better delineation of the tumour than the dedicated CT
scan. At least 95 % of the prescribed dose of 36 Gy in 15
fractions should cover 98 % of the PTV. The preoperative
radiochemotherapy schedule is depicted in Fig. 1.
Four weeks after the end of radiochemotherapy a CT
scan or MRI is repeated to rule out disease progression
by distant metastases and/or overt loco-regional pro-
gression and to measure the response according to the
RECIST criteria. Thereafter the patient is discussed again
by the multidisciplinary team and the exploratory lapar-
otomy is planned, provided that there is no progression.
Explorative laparotomy must be performed not earlier
than 14 weeks and no later than 18 weeks after
randomization. After resection, the remaining gemcita-
bine is administered at 1000 mg/m2/dose on days 1, 8,
and 15 in four cycles of 28 days (4 weeks) each to
complete a total of seven courses, two of which (courses
1 and 3) are modified in arm A.
Follow-up
Postoperative care takes place according to the institu-
tions’ routine guidelines. After randomization the pa-
tients will be followed up at 6 weeks, 3 months,
6 months and every 6 months thereafter, or more often
if the situation of the patient requires so. In both arms
there will be follow-up CT scans (or MRIs, at the discre-
tion of the participating institution) at 6, 12, 18 and
24 months, and yearly thereafter.
Safety
All participating institutions will be monitored for con-
duct of the trial according to good clinical practice
(GCP) standards, at least on a yearly basis [47].
An independent data monitoring committee (IDMC)
will monitor the safety of the trial subjects by qualitative
analyses of feasibility, accrual rate, and toxicity/morbid-
ity in the first years of the trial, after inclusion of the first
30 patients and thereafter, whenever it is considered ap-
propriate. One formal interim analysis for efficacy or fu-
tility is planned after 100 patients have been followed
until death or for at least 12 months after inclusion. Ser-
ious adverse events will be collected and recorded ac-
cording to the GCP throughout the study period,
Fig. 1 Treatment schedule
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defined as from randomization of the first patient
through 28 days after the last treatment of the last
patient.
Quality assurance radiotherapy
Every site will be asked to fill out a questionnaire and
provide data on a radiation plan of a patient with pan-
creatic cancer of whom the CT data are provided (a
dummy run). The quality assurance team (consisting of
at least two experienced radiation oncologists and a
physicist) will decide whether the provided plan is ad-
equate, and if not, give recommendations on how to im-
prove it. The results of this dummy run are in
preparation for publication.
Ethics
The study is performed in accordance with the declar-
ation of Helsinki and the Dutch Medical Research In-
volving Human Subjects Act (WMO) [48, 49]. The
protocol has been approved by the Medical Ethical
Committee of the Erasmus Medical Centre (MEC-2012-
249; date 11-12-2012).
Discussion
The PREOPANC trial investigates whether the addition of
preoperative radiochemotherapy to the standard treatment,
consisting of explorative laparotomy (if possible resection
via pancreatoduodenectomy or distal pancreatectomy)
followed by adjuvant chemotherapy, improves the overall
survival (by intention to treat) of patients with resectable
or borderline resectable pancreatic cancer (DPCG defin-
ition, Table 1). Preoperative radiochemotherapy may im-
prove resection rates as well as R0 resection rates and
hence improve overall survival [19–23, 33–38]. A major
difficulty in the interpretation of this literature is that most
studies are single arm studies that often only report on the
subset of patients actually undergoing a resection. This
hampers comparison of study results and disables proper
analysis of a potential increase in resection rate. From the
literature it is suggested that both patients with resectable
and borderline resectable tumours may benefit, but it is
hard to distinguish if this potential benefit differs between
these groups. Hence, the sample size in this study is not
calculated for both groups separately. Patients are stratified
by resectability status, and subset analyses are planned for
all endpoints, possibly leading to observational data on a
differential effect.
The treatment schedule in this study consists of full
dose gemcitabine (1000 mg/m2) combined with radi-
ation, adopted from previous phase II studies [25, 46]. In
these studies this radiochemotherapy regimen was well
tolerated and safe in patients with pancreatic cancer. It
also showed a favourable response rate in the pathologic
evaluation after resection [46]. The schedule is based on
the rationale that the chemotherapy dose in classical ra-
diochemotherapy schedules was considered too low for
the large proportion of early systemic failures in pancre-
atic cancer. Hence full dose chemotherapy was standard,
and a phase I dose-escalating study was performed con-
cerning the dose of radiation, leading to the relatively
low dose of radiation of 32 Gy in 15 fractions during the
middle course of chemotherapy.
In the experimental arm, a diagnostic laparoscopy is
performed before the preoperative radiochemotherapy,
to avoid a toxic, yet unnecessary treatment in patients
with peritoneal or small liver metastases that are not vis-
ible with imaging. Previous studies showed that laparo-
scopic staging avoided laparotomy in 35–40 % of the
patients with pancreatic cancer [50, 51]. All randomized
patients who do not undergo a resection for whatever
reason are considered a failure for the resection rate
endpoint.
The only way to evaluate the role of preoperative ra-
diochemotherapy in improving resection rate, R0 resec-
tion rate and thus overall survival is to perform a
randomized study, analysing the results by intention to
treat [37].
Trial status
The PREOPANC trial is a Dutch randomized, controlled,
multicentre trial, designed to investigate a potential im-
provement in overall survival for patients with (borderline)
resectable pancreatic cancer treated with preoperative ra-
diochemotherapy, followed by explorative laparotomy. The
study was opened in April 2013 with two active institu-
tions. At the time of submission of this paper (February
2016) 15 institutions were actively recruiting and 2 pend-
ing. A total of 148 patients were accrued in the trial on 6
March 2016.
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